immatics biotechnologies GMBH
immatics biotechnologies GMBH aims to identify tumor-associated peptides by directly measuring their presence in cancer tissue and then creating cancer vaccines from combinations of the most prevalent peptides associated with a particular tumor. The Tuebingen-based firm's proprietary platform combines genomics, mass spectrometry and cell-based assay systems to offer better speed and precision than existing technologies.
You may also be interested in...
PheneX Pharmaceuticals AG is a German biotech start-up formed by a management buy-out of certain drug discovery assets from Lion Bioscience. The firm has embraced a fee-for-service business model, aiming to leverage its expertise in nuclear receptor modulating compounds.
European developers of therapeutic cancer vaccines are making steady, if slow progress towards clinical and regulatory success. But late-stage setbacks and delays at North American firms-which are several years more advanced and thus bearing the brunt of working out the regulatory kinks-highlight the challenges associated with bringing a cancer vaccine to market. Given the various technological and commercial approaches to immunotherapy on either side of the ocean, European firms are closely watching the progress of similar technologies in the US.
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.